Comment on “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” i.e., all we are saying is, give C a chance
- 1 June 2011
- journal article
- editorial
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 50 (12) , 1726-1727
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radical Biology and Medicine, 2011
- Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic DiscoveriesAdvances in Nutrition, 2011
- Thermodynamic and kinetic considerations for the reaction of semiquinone radicals to form superoxide and hydrogen peroxideFree Radical Biology and Medicine, 2010
- Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse EffectsPLOS ONE, 2010
- Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic CancerClinical Cancer Research, 2010
- Phase I clinical trial of i.v. ascorbic acid in advanced malignancyAnnals of Oncology, 2008
- Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agentMedical Hypotheses, 1995
- High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior ChemotherapyNew England Journal of Medicine, 1985
- Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced CancerNew England Journal of Medicine, 1979
- The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancerChemico-Biological Interactions, 1974